NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. and the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) have reached an agreement to provide access to Schrödinger’s Materials Science, Biologics, and Small-Molecule Drug Discovery Suites to researchers within Tri-I TDI’s member institutions. The simulation tools are designed to advance early-stage research toward new therapeutics.
“We’re honored to be chosen as a technology platform provider for Tri-I TDI,” said Schrödinger’s president, Dr. Ramy Farid. “We believe our software will complement and contribute meaningfully to their ambitious goal of significantly accelerating drug-discovery projects.”
Help employers find you! Check out all the jobs and post your resume.
